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Abstract
Curcumin (CUR) is a phenolic compound present in some herbs, including Curcuma 
longa Linn. (turmeric rhizome), with a high bioactive capacity and characteristic yellow 
color. It is mainly used as a spice, although it has been found that CUR has interesting 
pharmaceutical properties, acting as a natural antioxidant, anti-inflammatory, 
antimicrobial, and antitumoral agent. Nonetheless, CUR is a hydrophobic compound 
with low water solubility, poor chemical stability, and fast metabolism, limiting its use 
as a pharmacological compound. Smart drug delivery systems (DDS) have been used 
to overcome its low bioavailability and improve its stability. The current work overviews 
the literature from the past 10 years on the encapsulation of CUR in nanostructured 
systems, such as micelles, liposomes, niosomes, nanoemulsions, hydrogels, and 
nanocomplexes, emphasizing its use and ability in cancer therapy. The studies 
highlighted in this review have shown that these nanoformulations achieved higher 
solubility, improved tumor cytotoxicity, prolonged CUR release, and reduced side 
effects, among other interesting advantages.
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Curcumin (CUR) is a bioactive compound and the main fraction derived from 
curcuminoids extracted from turmeric (Curcuma longa L.) rhizomes, a ginger family 
member (Zingiberaceae). This molecule is also known as Diferuloylmethane. The 
curcuminoids from C. longa have been extensively studied because of their anti-
inflammatory and antioxidant properties, and their potential activity as antitumoral, 
antibacterial, antioxidant, anti-inflammatory, antiviral, and antifungal agents (Abdel-
Wahhab et al., 2016; Alavi et al., 2018; Pushpalatha et al., 2019; Zielińska et al., 
2020a). However, the dietary and pharmacological application of native CUR is 
hindered due to poor water solubility and chemical instability, resulting in low 
bioavailability, fast metabolism, and predisposition to photochemical degradation 
(Alves et al., 2019; Altunbas et al., 2011; Olotu et al., 2020; Yallapu et al., 2012; Wang 
et al., 2016). One way to overcome these drawbacks can be the encapsulation of CUR 
to improve its water-solubility, stability, and consequently, the bioavailability of this 
phenolic compound.
One of the first studies related to CUR encapsulation in nanostructures (Ns) 
was published by Kuttan et al. (1985). These authors studied the encapsulation of 
CUR in liposomes (composed of phosphatidylcholine and cholesterol) and showed 
that after administering 1 mg of the nanoformulation (i.e., 50 mg/kg) per mouse, all 
animals survived up to 30 days, and only two of them developed tumors and died 
before 60 days. It was also observed that encapsulated CUR showed significantly 
higher capacity as an anticancer agent against Dalton's lymphoma cells than free 
CUR. After that, the scientific research involving the encapsulation of CUR to improve 
its pharmacokinetics and systemic bioavailability has grown considerably in the last 
years. However, most published works focus mainly on CUR therapeutic effects. 
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Comparative studies that address the stability of nanoencapsulated CUR and studies 
that effectively address the production engineering of Ns loaded with CUR are scarce 
or incomplete. Such studies are necessary to maximize Ns performance and enable 
their scale-up production.
Many (bio)materials such as polymers, amphiphilic copolymers, surfactants, 
lipids, and proteins have been evaluated as encapsulation matrices due to their 
biocompatibility, biomimesis, and biodegradability, with non-toxic metabolites upon 
physiological degradation (Naksuriya et al. 2014; Rafiee et al., 2018; Zielińska et al., 
2020b). In addition, the encapsulation of hydrophobic bioactive compounds such as 
CUR in Ns can render these compounds more hydrosoluble than their free 
counterparts, opening possibilities for more administration routes, including 
intravenous. Thus, nanobiotechnology provides a flexible method to overcome the 
limitations mentioned above, e.g., the poor water solubility of lipophilic bioactive 
compounds.
In this context, our focus in this work is to review the main aspects of CUR as 
a potential bioactive in nano-based drug delivery systems (DDS), including the 
characteristics, properties, and mechanism of action of this molecule, with a particular 
emphasis on its antitumor properties, as well as the latest developments regarding the 
Ns most employed for its encapsulation, focusing on works published during the last 
10 years. In the following sections, we also review therapeutic and pharmacological 
data of CUR loaded DDS, with a special emphasis on therapy against cancer.
2. Characteristics, properties, and mechanism of action of curcumin
Indian spice turmeric (C. longa) contains a mixture of curcuminoids, turmerin, 
and some essential oils (e.g., zingiberene, turmerones, and atlantones). Curcuminoids 
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represent only a fraction of approximately 2-9% of the total extract. These 
curcuminoids belong to the diferuloylmethane group of phenolic compounds and 
consist of CUR, demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC), 
with respective fractions of about 75, 10-20, and 5% (Patil et al., 2019; Ukrainczyk et 
al., 2016). These three major curcuminoids have similar chemical structures, 
distinguished only by the presence or absence of a methoxy functional group attached 
to each of the aromatic rings (Heffernan et al., 2017), as can be seen in Figure 1.
Figure 1. Chemical structures of curcumin (a), demethoxycurcumin (b), and 
bisdemethoxycurcumin (c) displaying the differences in the R1 and R2 groups between 
the three curcuminoids. Based on Heffernan et al. (2017).
CUR, in its pure form, is a solid crystalline compound with a golden-yellow color. 
Its IUPAC name is 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione, its 
chemical formula is C21H20O6 and show an average molecular mass of 0.36838 kDa. 
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CUR physicochemical characteristics include melting point at ~183oC, predicted log P 
of 3.2 (XLogP3-AA method), UV spectral peak (maximum in ethanol) at 426 nm, and 
two isomers. Other properties can be found in details in the following works or 
platforms: ChemSpider; DrugBank; Kotha and Luthria (2019); Kurnik et al. (2020; 
2021); Moghadamtousi et al. (2014); Patel et al. (2020); Prasad and Aggarwal (2011); 
PubChem; and Salem et al. (2014).
CUR can interfere with diverse biochemical pathways involved in the 
proliferation and survival of cancer cells by directly and indirectly binding to different 
targets. As highlighted by Salem et al. (2014), cancer has several molecular markers 
involved in its onset and progression. This molecule has been shown to interact with 
various targets, including transcription factors, growth factors, DNA, RNA, and several 
proteins involved in cell signal transduction pathways (Gupta et al., 2013; Shehzad et 
al., 2013a). CUR's mechanism of action can occur both intrinsically (mitochondrial) 
and extrinsically (mediated via cell surface transmembrane death receptors) (Shehzad 
et al., 2013b). The suggested pathways by which CUR shows anticancer properties 
have been described in detail in several interesting reviews (Epstein et al., 2010; 
Gupta et al., 2011; 2013; Patel et al., 2020; Salem et al., 2014; Shehzad et al., 2013a).
In particular, the antitumoral effect of CUR is highly related to its anti-
inflammatory effect. As highlighted by Alves et al. (2019) and Edwards et al. (2017), 
this effect is associated with the influence that this bioactive compound has on 
molecules involved in the cellular inflammation process, such as pro-inflammatory 
molecules, proteolytic enzymes, and cytokines. CCM can inhibit the production of 
interleukin 1 (IL-1), IL-6, IL-8, and IL-12, as well as tumor necrosis factor α. The effects 
of CCM on pro-inflammatory molecules may be associated with inhibition of the 
formation of arachidonic acid, an important eicosanoid substrate. CCM may also 
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inhibit the activity of enzymes such as cyclooxygenases and lipoxygenase, and the 
production of inflammatory mediators (prostaglandins). Based on in this anti-
inflammatory effect, as well as antioxidant and antitumoral properties, different CUR 
formulations have been developed and commercialized in the last years, such as: 
Meriva®, Cavacurmin®, Cureit®; Acumin®, Gelucire®, and BioCurc®. For more 
examples, we recommend the following works (Belcaro et al. 2014; Stohs et al., 2020).
Throughout the years, CUR effect on tumor cells has attracted significant 
attention and workload. In this context, we prepared a list of the most significant works 
related to different types of cancer treatments using CUR (Table 1).
Table 1. Summary of curcumin approach to cancer therapy in different types of tumor 
cells (according to cell line), as reported in the literature in the last 10 years.
Type of cancer and cell lines tested References
Breast cancer (HCC-38, UACC-3199, and T47D) cells Al-Yousef et al. (2020)
Leukemia (K562) cell Lestari et al. (2019)
Bladder cancer (T24 and UMUC2) cells Tian et al. (2017)
Colon adenocarcinoma (COLO 320DM) cell Dasiram et al. (2017)
Skin cancer (melanoma) Lelli et al. (2017)
Prostate cancer (DU145, PC3, and RPWE-1) cells Cao et al. (2017)
Lung cancer (A549) cell Liu et al. (2017)
Lung cancer (A549 and H1299) cells Zhu et al. (2017)
Leukemia (SHI-1) cell Zhu et al. (2016)
Breast cancer (MCF-7) cell Wang et al. (2016)
Lung cancer (A549 and PC-9) cells Jiao et al. (2016)
Skin squamous carcinoma (A431) cells Wu et al. (2015)
Skin cancer [BK5.IGF-1 transgenic mice that overexpress insulin-like 
growth factor-1 (IGF-1) in the skin epidermis]
Kim et al. (2014)
Human glioblastoma multiforme [A172, KNS60, U251MG(KO)] cells 
and medulloblastoma (ONS76) cell
Khaw et al. (2013)
Papillary thyroid cancer (K1) cell Zhang et al. (2013)
Cervical cancer (HeLa, SiHa, CaSki, and C33A) cells Singh and Singh (2011)
In this section, our objective was to show general characteristics, properties, as 
well as CUR mechanisms of action and not to make an in-depth discussion about each 
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specific topic. For more details by the interested reader in other therapeutic effects, 
we recommend the excellent following works: for antibacterial effect (Olszewska et al., 
2020; Prasad and Aggarwal, 2011; Tyagi et al., 2015; Winter et al., 2013); for 
antifungal effect (Garcia-Gomes et al., 2012; Lee and Lee, 2014; Neelofar et al., 2011; 
Sharma et al., 2010); and for antiviral effect (Dai et al., 2018; Mathew and Hsu, 2018; 
Moghadamtousi et al., 2014; Mounce et al. 2017).
3. Limitations of curcumin administration
Oral administration for systemic effects presupposes minimum water solubility, 
chemical stability under acidic (stomach) or around neutral pH (terminal jejunum and 
ileum), and mucosal absorption. CUR is practically water-insoluble (approximately 
1.34 mg/L) (Carvalho et al., 2015), unstable in neutral and mildly alkaline pH conditions 
(e.g., ~25% degradation after 10 h in pH 8.0 at 25°C) and presents debatable stability 
under acidic pH (Kurnik et al., 2020; Martínez-Guerra et al., 2019; Schneider et al., 
2015). For more details about its instability and degradation aspects, we recommend 
the interesting works of Alves et al. (2019) and Salem et al. (2014). As expected from 
its physicochemical profile, CUR demonstrates low bioavailability after oral ingestion, 
and is mostly found in feces. Clinical trials that evaluated CUR oral intake (0.5 to 12 
g/day), found CUR in the plasma with peak levels between 1-2 h, and traces or 
undetectable CUR up to 2 g/day. Studies vary on their dosage forms (tablets/capsules 
and food), different food intake regimes (empty stomach, with fat-rich meals, etc.), and 
CUR source (chemically synthesized, standardized extracts with other curcuminoids). 
Therefore, comparisons of peak levels between them should be cautious. Low plasma 
levels also derive from an extensive CUR metabolism mainly in the liver, followed by 
intestine and gut microbiota. However, several metabolic products also have 
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pharmacological properties, so metabolism itself may not impair treatment efficacy 
(Dei Cas and Ghidoni, 2019).
CUR low percutaneous permeation does not favor skin as an alternative route 
for its administration. However, an in vitro study with rat skin showed that CUR 
microemulsion substantially increased its permeation while emulsions had little effect, 
and demonstrated that transdermal application was possible by decreasing droplets’ 
average size (Sintov, 2015). In blood, CUR seems to be highly stable by binding to 
human serum albumin and fibrinogen because it precludes its degradation through 
hydrolysis (Leung and Kee, 2009). Also, CUR binding to bovine serum albumin (BSA) 
did not hamper in vitro CUR antioxidant and antiproliferative activities on cancer cells 
(Mirzaee et al., 2019). Therefore, CUR parenteral administration would pose solubility 
drawbacks. Despite this, toxicity studies in clinical trials find no limitations to CUR oral 
administration in humans so far, having been classified as Generally Recognized as 
Safe (GRAS). Noteworthy, an in vitro study using high CUR concentrations (10 to 40 
μg/mL) induced mitochondrial and nuclear DNA damage in human hepatoma G2 cells, 
but the phenomenon was not observed in vivo (Damarla et al., 2018).
In this context, in order to enhance CUR potential as a therapeutic agent in face 
of the above considerations, CUR encapsulation in Ns is an excellent alternative, not 
only to facilitate its absorption by the organism but also to protect it from degrading 
agents. Moreover, other characteristics such as the bioavailability and/or modified 
release can be improved by the use of Ns, and even properties such as the stability of 
CCM exposed to light can also be increased with nanoformulations. The surface of Ns 
allows different molecules to be attached to its structure [i.e., PEGylation, affinity 
ligands (e.g., transferrin and folate), imaging agents, among others], resulting in better 
targetability to the target site (e.g., cancer cells). In fact, the interesting stabilization 
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that nanoformulations offer for this molecule seems to be related to the hydrophobic 
interactions between CUR and the hydrophobic branches of the material/biomaterial 
which constitute the different Ns. This effect eliminates or considerably reduces 
interactions with water molecules in the medium, reducing or inhibiting the degradation 
of CUR by hydrolysis. As result, nanoformulations approach can allow the 
administration of CUR through different routes, such as mucosal, intravenous, oral, 
and topical. In addition, high plasma concentrations can be achieved with lower 
dosages, reducing side effects and maintaining therapeutic efficacy (Alves et al., 2019; 
Li et al., 2014; Salem et al. 2014; Zielińska et al., 2020a).
4. Main nanostructures for curcumin encapsulation
The Ns referred in this section increase CUR solubility and, at the same time, 
protected CUR against hydrolysis, enzymatic reduction, and conjugation inactivation, 
amongst others. Some nanoformulations aim prolonged CUR release, while others 
focus on targeting, using additional cellular delivery mechanisms or intracellular 
release. A formulation efficiently prepared and loaded should be capable to retain CUR 
for the required period.
The Ns selected by our research group to be discussed here are organic Ns, 
such as micelles, liposomes, niosomes, nanoemulsions, hydrogels, and 
nanocomplexes. This choice is based on the main discoveries using these Ns, as well 
as in our interest in these nanocarriers. Although an excellent work published by 
Naksuriya et al. (2014) emphasized the pharmaceutical properties, preclinical studies, 
and clinical data related to cancer treatment with CUR nanoformulations, a 
considerable amount of works were published the last 6 years that enlighten 
mechanism, structures or bring innovative solutions to this subject. Our focus here 
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was not to show the processes and techniques employed in obtaining Ns, but to show 
and compare the main results of CUR encapsulation in Ns, such as: size (nm); 
polydispersity index (PDI); zeta (ζ) potential; drug loading (%DL); efficiency of 
encapsulation (%EE); CUR release profile; and in vitro/in vivo cytotoxicity studies 
against tumor cells.
4.1. Micelles
Polymeric micelles (PMs) have gathered significant interest as DDS because 
of their low toxicity, good biocompatibility, modified release pattern, increased blood 
circulation time, and ability to solubilize hydrophobic drugs such as CUR in the 
micelles’ core (Akbar et al., 2018). The hydrophobic segments in the 
polymers/copolymers form the micelle core that acts as a reservoir for hydrophobic 
drugs, while the hydrophilic headgroups form the micellar shell that can improve the 
colloidal stability and prevent protein adsorption, thus prolonging the circulation time 
(Gou et al., 2011; Zhao et al., 2020). In particular, one type of material that is used as 
a biocompatible complexing agent to improve the water solubility, stability, and 
bioavailability of poor aqueous soluble drugs is Pluronic® copolymers, which contain 
hydrophobic poly(propylene oxide) (PPO) blocks and hydrophilic poly(ethylene oxide) 
(PEO) blocks arranged in a triblock structure, PEO-PPO-PEO. These attractive mixed 
PMs may be used as pharmaceutical carrier for CUR and other hydrophobic drugs 
(Akbar et al., 2018). Figure 2 shows the PMs structure with CUR encapsulated in its 
hydrophobic core.
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Figure 2. Schematic representation of polymeric micelles (PMs) obtained by 
amphiphilic copolymers. PMs can be spherical or cylindrical, with a hydrophobic core 
and hydrophilic surface and significantly more stable than surfactant-based micelles, 
based on Pachioni-Vasconcelos et al. (2015).
PMs are the Ns most used for encapsulating CUR as DDS for cancer therapy. 
In this section, we briefly present some research works employing CUR in PMs against 
tumor cells. Zhao et al. (2020) presented a redox-sensitive micellar system to 
overcome the multidrug resistance in cancer cells. Doxorubicin (DOX) and CUR were 
co-conjugated onto a zwitterionic polymer, poly(carboxybetaine) (pCB), to form CUR-
pCB-DOX that self-assembled into stable micelles. Those micelles presented a mean 
particle size of 164.2 nm, ζ potential of +32.1 mV, and PDI of 0.436, showed high 
colloidal stability in 10% fetal bovine serum solution at 37°C, and exerted significantly 
stronger antitumor activity against human mammary adenocarcinoma MCF-7 and 
MCF-7/Adr in vitro than individual delivery formulation (i.e., pCB-DOX + pCB-CUR) at 
the same concentrations of both drugs. Moreover, there was a significant reduction in 
the half-maximal inhibitory concentration (IC50) value of pCB-DOX (14.1 μg/mL) 
compared to the free DOX value (437.2 μg/mL), and co-delivery of pCB-DOX with 
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pCB-CUR further reduced the IC50 value to 8.9 μg/mL. Also, CUR-pCB-DOX exhibited 
the strongest cytotoxicity effect against MCF-7/Adr cells (5.87 μg/mL). The conjugate 
cellular uptake was enhanced due to the increased permeability and retention effect 
of tumor cells on the micellar conjugate.
Lachowicz et al. (2019) synthesized, in a simple one-step process via Steglich 
esterification, a bioconjugate of sodium alginate and CUR (AA-CUR), and used this to 
prepare stable calcium cross-linked spherical micelles serving as a delivery vehicle for 
CUR. The AA-CUR PMs showed a particle size of 200 nm, with high colloidal stability 
(ζ = -53.0 mV) and PDI of 0.200. Prolonged release of CUR was achieved for PMs 
during 5 h under physiological conditions (pH 7.4, at 37°C), with ~62 and 95% of CUR 
being released after 1 and ~4 h, respectively. To assess AA-CUR PMs cytotoxicity, 
mouse cancer cell lines from mammary carcinoma 4T1, melanoma B16F10, and colon 
carcinoma CT26-CEA and MC38-CEA were used. A dose-dependent sensitivity of all 
tested cancer cells to AA-CUR was observed. The IC50 values were 0.35, 0.175, 0.175, 
and 0.35 mg/mL for 4T1, B16F10, CT26-CEA, and MC38-CEA cell lines, respectively.
In another work, a dually loaded complex PM system was developed for co-
delivering DOX with CUR using a classic thin-film hydration method (Zhang et al., 
2018a). The in vitro safety and antitumor efficacy were evaluated on H9C2 cells by 
measuring viability and tumor growth inhibition in tumor-bearing mice, respectively. 
The results showed a %DL of 8.1% for CUR and 2.6% for DOX, and 98% of %EE for 
both CUR and DOX. The averaged particle size of freshly prepared nanoformulation 
was 35.7 nm with a mean PDI of 0.09, and ζ potential of -2.28 mV. The release profile 
was investigated for both drugs using PBS containing 0.5% Tween 80 at pH 3.5 as 
the medium to maintain the chemical stability during quantification. DOX showed a 
higher cumulative release rate (75%) than CUR (40%) within 72 h.
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Luong et al. (2017) developed nanomicelles composed of folic acid, styrene-
maleic acid, and curcumin–difluorinated (FA-SMA-CDF). In the active targeting 
approach, nanomicelles are typically conjugated/decorated with a targeting moiety, 
thereby facilitating the preferential accumulation of the drug in selected tissues, 
individual cancer cells, or intracellular organelles associated with specific recognition 
molecules in cancer cells. The FA-SMA-CDF nanomicelles' size and PDI values were 
191.3 nm and 0.176, respectively. Non-targeted (SMA-CDF) and targeted (FA-SMA-
CDF) nanoformulations had negative ζ potential values of -50.79 and -7.86 mV, 
respectively. The CDF loading in SMA-CDF and FA-SMA-CDF was 18.48 and 
10.44%, respectively. The IC50 values of CDF, SMA-CDF, and FA-SMA-CDF on 
SKOV 3 cells after 72 h were 0.65, 1.20, and 0.40 μM, respectively. FA-SMA-CDF 
micelles reduced the IC50 value of SMA-CDF by approximately 3-folds. A similar 
pattern of cell viability was observed in the case of HeLa cells, where IC50 values of 
CDF, SMA-CDF, and FA-SMA-CDF were found to be 0.70, 1.28, and 0.47 μM, 
respectively. Regarding A549 cells, the IC50 values of CDF, SMA-CDF, and FA-SMA-
CDF after 72 h were 1.65, 1.85, and 1.55 μM, respectively. In this sense, the results 
suggested the promising potential of FA-SMA-CDF for targeted anticancer therapy.
Zheng et al. (2016) developed CUR-loaded micelles using the copolymer 
monomethoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA). This work aimed to 
explore CUR-MPEG-PLA micelles' efficiency at a cellular level by investigating the 
drug uptake, apoptosis, and cytotoxicity to tumor cells in vitro. Biodegradable CUR-
MPEG-PLA micelles were applied against C6 and U251 glioma cells in vitro and in 
vivo to treat glioma cancer. Compared with free CUR, the cellular uptake and 
cytotoxicity were increased in vitro after CUR was encapsulated into PMs. The CUR-
MPEG-PLA micelles were characterized concerning average diameter (∼33 nm), PDI 
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(0.120), %DL (9.85%), %EE (98.5%), and ζ potential (-3.3 mV). The IC50 values of the 
nanoformulation on U251 cells were 29.02 and 6.82 μg/mL after 24 h and 48 h, 
respectively, while against C6 cells were 4.38 and 1.57 μg/mL after 24 h and 48 h, 
respectively. There was an increase of 40% in the amount of CUR released from the 
nanoformulation after 120 h, while the free CUR exhibited a high release level (40%) 
at 2 h. Furthermore, CUR-MPEG-PLA micelles showed significant effectiveness in 
suppressing glioma growth by inducing more cell apoptosis and inhibiting more cell 
proliferation and angiogenesis compared to free CUR. The authors considered that 
these formulations had the potential for clinical applications in glioma therapy.
The most significant results found in the literature on CUR-PMs for DDS 
approaches applied to cancer therapies are summarized in Table 2. The CUR-PMs 
nanoformulations size showed values from ~16.4 to 200 nm; the PMs with small size 
can sometimes exhibit long circulation times in vivo, which is a significant advantage 
for cancer therapy. In addition, the formulations were relatively monodisperse and 
stable, with interesting %DL (~3 to 16%) and %EE (88 to 99%) values, as can be seen 
in Table 2. Overall, the newly developed PMs encapsulated and delivered CUR 
efficiently in various cancer cell lines in vitro and into in vivo tumors, resulting in 
improved therapeutic efficacy of encapsulated CUR compared to treatments with free 
CUR. In addition to CUR, PMs could potentially be utilized to deliver any hydrophobic 
chemotherapeutic agents into tumors. These studies provide a strong rationale for the 
potential utilization of PMs as a promising anticancer therapy. 
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Table 2. Summary of curcumin-loaded polymeric micelles (PMs) approach for cancer therapy reported in the literature over the past 
10 years. PDI, %DL, %EE, and IC50 correspond to polydispersity index, drug loading, efficiency of encapsulation, and half-maximal 
inhibitory concentration, respectively.
Type of polymeric micelles 




%DL %EE IC50 Release results Cell lines evaluated References
PMs composed by Pluronic 













Both after 2.5 h
Human prostatic 
carcinoma (PC3) cell 
line























89.7% of CUR after 
30 h with 
10 mM GSH
92.4% of DOX after 








Zhao et al. 
(2020)
Bioconjugate of sodium 
alginate – CUR cross-linked 
with calcium
178 – 200 0.200 – 0.290
-53.0 –
-25.9 - -
0.35 mg/mL (4T1) 





~62% after 1 h 
95% after ~4 h
Mammary carcinoma 
(4T1), melanoma 

















43.2% after 24 h in 
GSH (pH 7.4)
22.7% after 24 h 
without GSH 
(pH 5.0) 




Tian et al. 
(2018)
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PMs composed by 
Pluronics P123 and PF127 













- - Human cervical cancer (HeLa) cells
Akbar et al. 
(2018)
Complex PMs co-
encapsulating DOX and 
CUR
35.7 0.090 -2.28 8.1 (CUR)2.6 (DOX) 98 (both) -
40% after 72 h 
(CUR)
75% after 72 h 
(DOX)
In vitro viability of 
H9C2 cells, and tumor 
growth inhibition in 
tumor-bearing mice



















7% after 24 h
45% after 72 h 
(CUR-P407)
76% after 24 h




Tima et al. 
(2017)
Folic acid – styrene-maleic 
acid – curcumin – 
difluorinated







human cervical cancer 
(HeLa), and human 
lung cancer (A549) 
cells












0.488 -18.2 11.86 93.74 - 69.83% after 24 h
Murine melanoma 
(B16F10) and human 
breast cancer 
(MDA-MB-231) cells
Kumari et al. 
(2017)






∼33 0.120 -3.3 9.85 98.5
29.02 μg/mL after 24 h
6.82 μg/mL after 48 h
(with CUR-MPEG-PLA 
both to U251)
43.37 μg/mL after 24 h
10.38 μg/mL after 48 h
(with free CUR both to 
U251)
25% after 24 h
>40% after 120 h
Glioma 
(C6 and U251) cells
Zheng et al. 
(2016)
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4.38 μg/mL after 24 h 
1.57 μg/mL after 48 h
(with CUR-MPEG-PLA 
both to C6)
4.74 μg/mL after 24 h 
1.97 μg/mL after 48 h
(with free CUR both to 
C6)






27.3 0.097 - ~13 99.1
5.78 μg/mL 
(CUR-MPEG-PCL)
3.95 μg/mL (free CUR)
54.6% after 9 days Colon carcinoma (C-26) cell
Gou et al. 
(2011)
"-” this parameter was not reported by the authors;
[Ch][Hex]: cholinium hexanoate, and [Ch]Cl: cholinium chloride;
Abbr.: Abbreviation of the formulation used by the authors;
GSH: overexpressed glutathione; DMSO: dimethyl sulfoxide; and DTT: dithiothreitol. 
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4.2 Liposomes
Liposomes (LSs) are self-assembled systems. They are colloidal nano- to 
micro-sized vesicles, having at least a lipid bilayer that encloses an aqueous core. 
The wall of LSs is made of phospholipids purified from natural or synthetic 
sources, and it can incorporate hydrophilic, hydrophobic, and photo-instable 
drugs as illustrated in Figure 3a (Momoh and Esimone, 2012; Riaz et al., 2018; 
Sercombe et al., 2015). The natural phospholipid sources are phosphatidylserine 
and phosphatidylcholine, which can be obtained from soy and egg yolk, 
respectively. The synthetic phospholipids are synthesized from glycerol-
phosphocholine and maintain the stereochemical configuration of its molecule-
pair from the natural source (van Hoogevest, 2017). Some of them can be 
previously designed for a specific function from PEG-lipid conjugates 
incorporating functionalized PEG termini, like amine, carboxylic acid, azide, 
aldehyde, thiol, and hydroxy (Figure 3b). The PEGylated systems are a valuable 
strategy for creating a steric stabilization effect at the surface of LSs, increasing 
repulsive forces between LSs and serum-components (Dhule et al., 2012). 
Moreover, modified LSs have also been highlighted as a multifunctional 
theragnostic agent for multimodal imaging, induced photodynamic therapy (PDT) 
(Figure 3c), hypoxia-activated cancer therapy, and trigger chemotherapy, 
resulting in a significantly improved efficacy compared to conventional cancer 
PDT (Feng et al., 2017).
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Figure 3. Schematic diagram of liposomes (LSs): (a) conventional LSs are made 
of phospholipids; (b) PEGylated/stealth LSs contain a layer of polyethylene glycol 
(PEG) at the surface of LSs; (c) theranostic LSs contain image agents with 
multifunctional characteristics; (d) targeted LSs contain a specific targeting ligand 
to target a specific site. Based on Sercombe et al. (2015).
As shown in Figure 3d, to achieve LSs manifold functionalization, a 
suitable ligand, peptide, antibody or their fragments, aptamer, small molecule, 
protein, and carbohydrate are requested for DDS (Riaz et al., 2018; Sercombe et 
al., 2015). The termini groups attached to the PEG-modified functional coatings 
improves LSs biopharmaceutical properties by increasing its circulation time, 
often by avoiding uptake by the reticuloendothelial system, by improving its 
accumulation and cellular internalization, and amplifying the therapeutic 
response at the surface of the tumor cells.
The LSs surface modification, as well as the size and number of bilayers 
as detailed in Figure 3e can be used to control LSs properties in a convenient 
way and get several different functions arranged simultaneously, especially to 
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assist drug delivery in cancer areas and overcoming CUR drawbacks in 
conventional pharmacotherapy, by enhancing its bioavailability, circulation time, 
and reducing its photo-instability.
Probably, LSs are the most used structures for CUR encapsulation, after 
micelles. In this context, we discussed here some works related to CUR within 
liposomal nanoformulation. Xu et al. (2018) developed an LS composed of 
soybean phosphatidylcholine, cholesterol, and CUR (CUR-LS) for endometrial 
carcinoma treatment. According to DLS analyses, the average particle size, PDI, 
and the ζ potential of the CUR-LS were 126 nm, 0.057, and -8.88 mV, 
respectively. The IC50 values of CUR-LS against human endometrial carcinoma 
Ishikawa and HEC-1 cell lines were 52.8 and 80.8 μM, respectively. CUR-LS 
treatment suppressed the activation and/or expression of nuclear factor kappa B 
(NF-κB), caspase-3, and matrix metalloproteinase-9.
Zhang et al. (2018b) developed a liposomal curcumin dry powder inhaler 
(LCDs) obtained by freeze-drying, composed of soybean lecithin and cholesterol, 
to treat primary lung cancer by inhalation. According to DLS analyses, the 
average particle size and PDI of LCDs nanoformulation were 94 nm and 0.260, 
respectively. This formulation had a mass mean aerodynamic diameter of 5.81 
μm and a fine particle fraction of 46.7%, and was suitable for pulmonary delivery 
than CUR powders due to the high lung deposition of LCDs. The IC50 value for 
A549 cells was 20 μmol/L, and the low cytotoxicity on normal human bronchial 
BEAS-2B epithelial cells yielded a high selection index partly due to increased 
cell apoptosis. This formulation showed to be a promising inhalation treatment for 
lung cancer with high therapeutic efficiency.
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CUR-LS surface modified with hyaluronic acid can target a cell-surface 
glycoprotein involved in cell-cell interactions (CD44) and provide effective 
treatment in acute myeloid leukemia by inhibiting cell growth. These modified 
CUR-LSs generated caspase-dependent apoptosis, inhibition of the activation of 
protein kinase B (Akt), and the extracellular expression of the signal-regulated 
kinase (ERK), also impacting the Akt/ERK signaling pathways. This strategy has 
been adopted by Sun et al. (2017), who developed a novel LSs system 
functionalized with hyaluronic acid and composed by a combination of 1,2-
dimyristoly snglycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (DMPG), amine 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG 2000), 
1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol (DSPE) and cholesterol, 
named as HA-CUR-LSs. This nanoformulation showed an average particle size, 
PDI, and ζ potential of 236 nm, 0.232, and -36.8 mV, respectively. Regarding 
CUR encapsulation, the %DL and %EE showed values of 13.2 and 66%, 
respectively. The CUR released in vitro was 60.0% and 95% after 48 and 144 h, 
respectively. Moreover, the IC50 for acute myeloid leukemia cells was 10.9 μM, 
indicating that HA-CUR-LSs enhanced the antitumor potency of CUR via this 
liposome formulation with HA modification.
CUR and DOX association into LS also demonstrated antitumor efficacy 
against colorectal cancer (Sesarman et al., 2019). These authors developed a 
PEGylated CUR-LS associated with DOX, with LSs composed of 
dipalmitoylphosphatidylcholine (DPPC), PEG-2000-DSPE, and cholesterol. 
According to the results obtained, the average particle size, PDI, and ζ potential 
were 171 nm, 0.033, and -48.7 mV, respectively. The %DL and %EE values were 
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0.72 and 99.4%, respectively, and the CUR release from the LSs after 24 h was 
of 20%. CUR-DOX-LS showed an inhibition of the main tumor microenvironment-
mediated protumour processes such as angiogenesis, inflammation, oxidative 
stress, invasion, and resistance to apoptosis, as well as to the alteration of T 
helper cells (Th1/Th2) axis in C26 colon carcinoma milieu, which favored the 
antineoplastic phenotype of cells.
Table 3 summarizes the most significant LS-based delivery systems of 
CUR developed during the last 10 years and used to treat different cancer types. 
LSs are versatile nanocarriers, since they enable the encapsulation of hydrophilic 
and hydrophobic drugs in their nanostructure, however, in general they are larger 
than PMs, for example. According to Table 3, the LSs size displayed values of 86 
to 414 nm, many of these values being greater than 200 nm. The large size (>200 
nm) can result in clearance by the reticuloendothelial system, consequently 
eliminating the molecule from the bloodstream (Wang et al., 2013). In summary, 
the liposomal nanoformulations highly enhance the effect of CUR by overcoming 
the water solubility limit and increasing cell endocytosis. Moreover, LSs show to 
be an effective carrier to enhance the stability, bioavailability, and targeting 
properties of CUR.
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Table 3. Summary of curcumin-loaded liposomes (LSs) approach for cancer therapy reported in the literature over the past 10 years. 
PDI, %DL, %EE, and IC50 correspond to polydispersity index, drug loading, efficiency of encapsulation, and the half-maximal inhibitory 
concentration, respectively.
Type of liposomes 









Thiolated chitosan coating 
liposome/L-α-phosphatidylcholine, 
cholesterol
414 - +37.3 3.96 88.7 - 76.6%after 12 h
Human breast 
cancer (MCF 7) cells
Li et al. 
(2020)
Aptamer A15 coating liposome/egg 
phosphatidylcholine, DSPE-PEG 
(2000), and cholesterol




Ma et al. 
(2019)
PEGylated coating/DPPC, DSPE-
















Sesarman et al. 
(2019)
Cationic liposome/DOTAP, DOPE, 
C6 ceramide, and sodium cholate 142 0.242 +42.8 10 86.8 - -
Melanoma (B16F10) 
cells Jose et al. (2018)
Conventional liposome/composed 
by soybean phosphatidylcholine 
and cholesterol
126 0.057 -8.8 - -
52.8 μM for 
Ishikawa cells






Xu et al. 
(2018)
Conventional liposome/cholesterol, 
DSPE-mPEG-2000 and DMPC 294 0.119 +10.8 3.42 93.4 0.62 μM
74% 
after 24 h
Human liver cancer 
(HepG2) cells Cheng et al. (2018)
Hyaluronic acid coating 
liposome/cholesterol, DMPC, 
DMPG, DSPE, and DSPE-PEG (2000)
Abbr.: HA-CUR-LSs













KG-1, and MV4-11) 
cells
Sun et al. 
(2017)
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Type of liposomes 














211 0.290 -22.6 3.0 83.5
16.1 μM










Duse et al. (2017)
PEGylated coating 
liposome/phosphatidyl-choline, 





























Ruttala and Ko 
(2015)
Cationic liposome/soybean lecithin, 
Montanov82®, and DDAB 
(Abbr.: CUR-LSD) or soybean 






















21 μM for HeLa
16 μM for SiHa







HPV type 18 
positive (HeLa) cells 
and Human cervical 
tumor (SiHa) cells
Saengkrit et al. 
(2014)
“-” this parameter was not reported by the authors;
Abbr.: Abbreviation of the formulation used by the authors;
DMPC: Dimyristoylphosphatidylcholine; DMPG: 1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol, sodium salt; DOTAP: 1,2-dioleoyloxy-3-(trimethylammonium) propane; DPPC: 
Dipalmitoylphosphatidylcholine; DSPE: 1,2-distearoyl-sn-glycero-3-phospho-rac-glycero; DSPE-PEG (2000): Amine 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000]; PTX: paclitaxel; and DOX: doxorubicin. 
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4.3 Niosomes
Nonionic surfactant vesicles, also known as niosomes (NIOs) are colloidal 
particles formed from the self-assembly of nonionic surfactants with or without 
cholesterol moieties in aqueous media, which results in a microscopic lamellar 
bilayer structure. The schematic representation NIOs structure is given in Figure 
4. Structurally, NIOs are similar to liposomes and polymersomes, nanostructures 
that consist of a bilayer composed of phospholipids or copolymers, respectively. 
However, NIOs high chemical stability and economy make them superior to 
liposomes (Ashutosh et al., 2012). NIOs are microscopic lamellar structures (10 
to 1,000 nm) which amphiphilic nature allows the entrapment of hydrophilic drugs 
in the core cavity and hydrophobic drugs in the non-polar region present within 
the bilayer (Ashutosh et al., 2012).
Figure 4. Schematic representation of niosomes (NIOs). NIOs are vesicles 
composed mainly of hydrated nonionic surfactants (such as series of Brijs, 
Spans, and Tweens), in many cases, added of cholesterol or its derivatives, 
based on Moghassemi and Hadjizadeh (2014).
NIOs are emerging in the DDS area due to their salient features such as 
biodegradability, biocompatibility, chemical stability, low production cost, low 
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toxicity, and easy storage and handling. Therefore, NIOs have been evaluated 
as carriers to deliver a vast number of anticancer drugs, genes, antigens, and 
other bioactive compounds (Bagheri et al., 2014).
Seleci et al. (2017) encapsulated DOX and CUR in polyethylene 
glycolated NIOs (PEGNIO). This research group employed the thin-film hydration 
method. To obtain high cellular internalization, PEGNIO surface was conjugated 
with a penetrating peptide (tLyp-1). The empty PEGNIO was 150 nm, while after 
co-encapsulation of the two drugs, the diameter obtained was 144 nm. The tLyp-1 
peptide conjugation efficiency was 23.9%, and it did not change the formulations’ 
size considerably since the PDI values ranged from 0.140 to 0.175. For CUR and 
DOX, the %DL was 32.6 and 23.3%, respectively. Within 32 h the release profiles 
of CUR and DOX at acidic pH (5.6) was 62 and 74%, respectively; and at 
physiological pH (7.4), the release values were 36 and 68%, respectively. The 
IC50 values were calculated to be 0.96, 0.90, and 0.76 µg/mL for DOX–CUR, 
PEGNIO/DOX-CUR and PEGNIO/DOX-CUR/tLyp-1, respectively. In both 
combinatory studies (i.e., CUR and DOX), the results indicated that NIOs are a 
promising DDS for hydrophobic and hydrophilic drugs together and showed that 
the use of functionalized NIOs could increase drugs cytotoxicity against cancer 
cells.
In another study, Sharma et al. (2015) also investigated CUR and DOX 
encapsulation in NIOs and their release. These authors used the film hydration 
method to prepare NIOs by amphiphilic self-assembly of Tween-80 and 
cholesterol. The NIOs size and ζ potential values were 220 nm and -24 mV, 
respectively. Regarding the molecules’ distribution, DOX hydrochloride 
(DOX·HCl) was encapsulated in the aqueous inner due to its hydrophilic 
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character, while CUR was encapsulated in the outer lipid bilayer because of its 
hydrophobicity. The %EE achieved for CUR and DOX was approximately 90 and 
25%, respectively. The release profile showed that 79% of DOX is released within 
two days, followed by 70% CUR up to 1 week. The IC50 value of dual drug-loaded 
NIOs against HeLa cell lines was 1.8 μg/mL, which increased to 2.7 and 7.2 
μg/mL for free DOX and CUR, respectively.
According to Puvvada et al. (2013), NIOs can be used in DDS as a 
substitute for liposomes, showing enhanced stability and biocompatibility. In this 
study, the group obtained NIOs for CUR encapsulation using poly (ethylene 
glycol) methyl ether acrylate (PEGMEA480) conjugated with cysteine (PEG-Cys). 
The average size of nanoformulations without (PEG-Cys-NIO) and with CUR 
(PEG-Cys-NIO-CUR) was found to be in the range of 160 to 185 nm and 160 to 
210 nm, respectively. The cytotoxicity of both nanoformulations in cultured 
human breast cancer cell line (MCF7) showed that 30% cell viability was 
achieved with 40 µM of free CUR, while 25 µM of PEG-Cys-NIO-CUR was 
needed to achieve the same percentage of cell viability. Further, the group 
observed that free CUR showed an IC50 of 27 µM, whereas PEG-Cys-NIO-CUR 
IC50 was of 17 µM after 24 h of treatment.
Table 4 summarizes the main studies that address the preparation of 
CUR-NIOs nanoformulations for cancer therapy. The works found and 
highlighted by us, demonstrate that these nanoformulations are a promising 
therapeutic strategy against different types of cancer cells, such as human 
glioblastoma, ovarian cancer therapy, human breast cancer, and cervical 
carcinoma, among others. The NIOs size displayed values of 84 to 220 nm, these 
Ns were relatively monodisperse and stable. The IC50 values found for the CUR-
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NIOs formulation have shown that less drug concentration (including when CUR 
is administered in combination with another drug, e.g., DOX and PTX) can be 
administered to achieve the same cytotoxic effect regarding to free CUR, this 
effect is an advantage because it can generate a considerably reduction of side 
effects in cancer therapy, according to Table 4. Overall, NIOs seem to be an 
interesting DDS to suppress CUR degradation level compared to the 
conventional surfactants forming normal micelles. The rigidity of the NIO 
membrane, due to the presence of cholesterol moieties in the niosomal bilayer, 
increases the level of interaction between CUR and the oxyethylene units of 
nonionic surfactants molecules (e.g., Tween-20 or Tween-80), while in normal 
micelles this type of interaction is not so strong because of the higher water 
accessibility on the hydration layer (Mandal et al., 2013). Other important 
observation related to NIOs is that the metabolic fate can be difficult to express, 
since some compounds used may not be biodegradable.
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Table 4. Summary of curcumin-loaded niosomes (NIOs) approach for cancer therapy reported in the literature over the past 10 years. PDI, %EE, 
and IC50 correspond to polydispersity index, efficiency of encapsulation, and the half-maximal inhibitory concentration, respectively.
Type of niosomes systems/Composition Size (nm) PDI ζ potential (mV) %EE IC50 Release results Cell lines evaluated References
Cationic PEGylated niosomal formulations 
containing Tween-
60:cholesterol:DOTAP:DSPE-mPEG with 
combination of paclitaxel (PTX) and CUR
































Alemi et al. 
(2018)
Polyethylene glycolated niosomes composed 
by Span-60, cholesterol, and DSPE-PEG 
























~36% after 12 h
~40% after 24 h
~62% after 32 h
(CUR at pH 5.6)
~15% after 12 h
~35% after 24 h
~36% after 32 h
(CUR at pH 7.4)
~60% after 12 h
~62% after 24 h
~74% after 32 h
(DOX at pH 5.6)
~48% after 12 h
Human glioblastoma 
(U87) cells
Seleci et al. 
(2017)
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~50% after 24 h
~68% after 32 h
(DOX at pH 7.4)
Combination of nonionic surfactants (Span-
80, Tween-80, and Poloxamer-188) 
Abbr.: CUR-NIO
84 - -25 –-20 92.3 -
45% after 6 h





Nonionic surfactant Tween-80 and 









~15% after 12 h
~25% after 24 h
~50% after 72 h
(CUR at pH 7.4)
~15% after 12 h
~25% after 24 h
~55% after 72 h
(CUR at pH 5.5)
~65% after 12 h
~65% after 24 h
(DOX at pH 7.4)
~70% after 12 h
~80% after 24 h
(DOX at pH 5.5)




Poly(ethylene glycol) methyl ether acrylate 
(PEGMEA-480) conjugated with cysteine
Abbr.: PEG-Cys-NIO-CUR
160 – 210 -
~+6.5





(24 h for PEG-Cys-NIO-
CUR)
27 µM 
(24 h for free CUR)
~6% after 24 h
~8% after 48 h
~12% after 72 h
(PEG-Cys-NIO-CUR 
at pH 7.0)
~30% after 24 h
~55% after 48 h
~70% after 72 h
(PEG-Cys-NIO-CUR 
at pH 5.0)




“-” this parameter was not reported by the authors;
Abbr.: Abbreviation of the formulation used by the authors;
DOX: doxorubicin hydrochloride; and (DSPE-PEG (2000) Maleimide): 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000]. 
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4.4 Nanoemulsions
Nanoemulsions (NEs) are biphasic dispersions, where one phase is 
dispersed in another phase [either oil-in-water (o/w) or water-in-oil (w/o) droplets] 
and stabilized by an emulsifier that reduces the interfacial tension between the 
two immiscible liquids (Jiang et al., 2020). NEs can present a mean droplet 
diameter between 20 to 200 nm (Figure 5), despite the lack of a current 
consensus on the upper limit (Choi and McClements 2020). Different emulsifiers 
such as biopolymers (e.g., proteins and polysaccharides), phospholipids, 
surfactants (e.g., Tween 80), and oils (e.g., fats and essential oils) can be used 
to produce NEs (Choi and McClements, 2020; Pinheiro et al., 2016; Salvia-Trujillo 
et al., 2017).
Figure 5. Schematic representation of oil-in-water (o/w) nanoemulsion (NEs) 
loaded with a hydrophobic drug, curcumin (CUR). NEs are formed by nano-scale 
droplets that contain an oil phase in the core dispersed in bulk aqueous phase 
(or vice-versa – w/o), with the help of an interfacially active compound (i.e., 
surfactant). Based on Yoon et al. (2018) and Pachioni-Vasconcelos et al. (2015).
NEs have attracted significant attention due to their promising ability to 
encapsulate bioactive compounds for numerous applications in food, 
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pharmaceutical, and medical areas. Among the various nanoformulations, NEs 
are particularly suited for lipophilic compounds such as CUR to enhance their 
solubility and bioavailability. Besides, NE exhibits greater stability to gravitational 
separation and droplet aggregation than conventional emulsions (Choi and 
McClements, 2020). Therefore, several studies have been performed to show the 
prospect of using NE to create CUR delivery systems (Ahmad et al., 2019; 
Beloqui et al., 2016; Rafiee et al., 2018; Sari et al., 2015).
NEs must be thermodynamically stable and transparent. Nonetheless, the 
formation of NEs requires energy because they are non-equilibrium systems. 
Thus, CUR can be encapsulated in NEs using low or high energy methods. Low 
energy methods comprise the formation of oil droplets through the control of 
interfacial modification at the boundary between two immiscible phases and rely 
on the nature (i.e., molecular structure and solubility) of the molecules existing in 
the solution (Rafiee et al., 2018). On the other hand, high energy methods rely 
on high disruptive forces that physically break the oil droplets into fine droplets 
dispersed within the aqueous phase (McClements and Rao, 2011; Salvia-Trujillo 
et al., 2017). Usually, low energy methods are more efficient in producing smaller 
emulsions, but high energy methods have some advantages: e.g., the need for 
lower levels of emulsifiers and scale-up simplicity.
Some in vitro and in vivo research works have been conducted to assess 
the therapeutic performances (e.g., anticarcinogenicity), biological efficacy, and 
safety profile of NEs incorporating CUR. Studies have also shown that CUR 
encapsulated in NEs improved its anticancer effect compared with free CUR. For 
instance, Nikolic et al. (2020) developed low-energy NEs stabilized by 
polysorbate 80 and soybean lecithin as delivery systems for CUR and assessed 
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their therapeutic performance and safety profile. CUR-NE had a mean size 
diameter of <150 nm with a PDI ranging from 0.156 to 0.175. Cytotoxicity tests 
demonstrated that CUR-loaded NE possessed significant cytotoxic activity 
towards HeLa cell line (IC50 = 22.89 μg/mL) and human malignant melanoma 
(Fem-x cell line, IC50 = 37.87 μg/mL). On the other hand, free CUR presented IC50 
values of 7.77 and 20.64 μg/mL for HeLa and Fem-x cell lines, respectively. The 
authors also stated that encapsulation raised CUR-NE safety profile compared to 
free CUR, the IC50 values towards normal lung fibroblast (MRC-5) cell line for 
CUR-NE and free CUR were 67.72 and 26.97 μg/mL, respectively.
In another study, CUR-o/w-NE prepared with Miglyol 812 (as oil), Epikuron 
145 V (as surfactant), ethanol, and acetone by spontaneous nanoemulsification 
method showed anticancer efficacy (Guerrero et al., 2018). The average size, 
PDI, and ζ potential of the CUR-loaded NE were in the range of 195 to 217 nm, 
<0.200 and -30 to -36 mV, respectively. The %EE and %DL of CUR in the NE 
were 95 and 2.1%, respectively. Cell viability following treatment with CUR-
loaded NE was assessed in various cancer cell lines, namely human gastric 
adenocarcinoma (AGS), colorectal adenocarcinoma (HT29-ATCC), cells derived 
from HT29-ATCC with elevated metastatic potential (HT29-US), human 
mammary gland adenocarcinoma (MDA-MB-231), and murine melanoma 
(B16F10). The observed IC50 values were 24, 26.2, 75.7, and 84.6 μM for AGS, 
MDA-MB-231, HT29-US, and HT29-ATCC cells, respectively, which indicated 
that this nanoformulation reduced cancer cell proliferation.
Other CUR-NE were developed using soy phospholipids (Lipoid S100), 
and surfactant poloxamer 188, and their effect as a potential natural 
photosensitizing drug in PDT for breast cancer (MCF-7 cell line) was studied 
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(Machado et al., 2019). The mean size diameter, PDI, and ζ potential of the CUR-
NE were 199 nm, 0.179, and -46.3 mV, respectively. The results showed that the 
application of CUR-NE in PDT resulted in a desirable phototoxic effect (cell 
viability reduce to 57%) and increased reactive oxygen species generation in 
MCF-7 breast cancer cell line. In another study, CUR was formulated into o/w NE 
obtained with black pepper oil (oil phase) and Tween 80 (surfactant) at 1:9 ratio, 
and the in vitro cytotoxic effect of these NEs was assessed in Neuro2A cells (a 
fast-growing mouse neuroblastoma cell line) (Moghaddasi et al., 2018). CUR-NE 
were obtained with a mean particle size of 25.0 nm, PDI of 0.286, and ζ potential 
of -9.61 mV. Cytotoxicity was detected in the treated Neuro2A cells when CUR-
NE were applied up to 15.63 μg/mL. The authors suggested that this CUR-NE 
could be potentially used as a cancer treatment.
Table 5 summarizes the most significant studies published during the last 
10 years, regarding CUR-NEs delivery systems for cancer therapy. The CUR-
NEs size showed values from ~34 to 202 nm, the values of PDI and zeta potential 
varied of 0.129 to 0.510, and -42 to -8.5 mV, respectively. In general aspects, 
CUR-NEs showed a good controlled and sustained release, as can be seen in 
Table 5. Interestingly, NEs can enable new delivery routes, for example, for the 
oral CUR delivery. In this case, Shukla et al. (2017) showed that CUR-NEs 
improved anticancer activity, as highlighted by this group this effect could be 
related to the enhanced oral bioavailability of CUR from NEs formulation. In 
addition, the mentioned researches demonstrate the potential of using NE to 
create CUR delivery systems with anticancer potential. Results obtained from the 
literature provide a basic knowledge of the cytotoxicity of NE on various cell types 
and can be used as a basis for future animal experiments. 
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Table 5. Summary of curcumin-loaded nanoemulsions (NEs) approach for cancer therapy reported in the literature over the past 10 
years. PDI and IC50 correspond to polydispersity index, and the half-maximal inhibitory concentration, respectively.
Type of nanoemulsions 
systems/Composition Size (nm) PDI
ζ potential 











0.300 - - -
Mouse fibroblasts 
(NIH3T3) cells











Yoon et al. (2018)
SNEDDS of CUR-phospholipid 
complex: CUR, phospholipid (L-ɑ-
phosphatidylcholine from 










~5% of CUR after 2 h in 
SGF, pH 1.2 and ~30% 
of CUR after 24 h 
in SIF, pH 6.8 (CUR 
suspension)
~10% of CUR after 2 h 
in SGF, pH 1.2 and 
~40% of CUR after 24 h 
in SIF, pH 6.8 (CUR-
phospholipid complex)
~15% of CUR after 2 h 
in SGF, pH 1.2 and 
93.1% of CUR after 24 





Shukla et al. (2017)
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Type of nanoemulsions 
systems/Composition Size (nm) PDI
ζ potential 




CUR, MCT, cremophor RH 40, and 
glycerol
34.54 0.129 -8.54 -
30% of CUR was 
released from NE at 





Guan et al. (2017)
w/o NE based lipid nanosystems:
CUR, ethyl oleate, water, CEL 35, 
PEG 400, glycerin monostearate, 
Lipoid S 75, and Tween 80
121 - -42
15 μM 
after 24 h (15.59%) 
12.5 μM 
after 48 h (23.22%)
9 μM 
after 72 h (41.10%)
~70% after 
170 h in pH 1.2 HCl 
solution (containing 
0.5% SDS and 20% 
ethanol) and in pH 6.8 
PBS
~70% after 
170 h at pH 6.8 (PBS)
Human lung cancer 
(A549) cells
Wan et al. 
(2016)
Lipid NE:
CUR, soybean oil, HEPC from egg 
















25% (in human serum 
containing PBS at pH 
7.4) 
1.4% (in PBS alone)
Both after 72 h














“-” this parameter was not reported by the authors;
CEL 35: Cremophor EL 35; HCO-60: Cremophor-HR60; HEPC: hydrogenated L-α-phosphatidylcholine; MCT: medium chain triglyceride; o/w: oil-in-water; PBS: Phosphate-
buffered saline; PEG: polyethylene glycol; SDS: sodium dodecyl sulfate; SIF: simulated intestinal fluid; SGF: simulated gastric fluid; SNEDDS: self-nanoemulsifying drug delivery 
system; and w/o: water-in-oil.
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4.5 Hydrogels
Hydrogels (HGs) began to be explored in 1960, although the origin of the 
term “hydrogel” appeared in 1894 and was first marketed in 1949 with the 
application of poly(vinyl alcohol) cross-linked with formaldehyde for biomedical 
implants (Cascone and Lamberti, 2020; Wichterle and Lím, 1960). After long 
years of industrial applications, HGs have been widely studied because of their 
three-dimensional networks, non-solubility in water at a physiological 
temperature or pH, noticeable swellability in aqueous media, and porosity formed 
by physical (e.g., hydrogen bonds, entanglement of chains, ionic gelation, and 
van der Waals interactions) or chemical (simple monomers reaction - covalent 
bonds) cross-linking of molecules, as depicted in Figure 6. These characteristics 
allow water absorption and retention in the interstitial spaces between chains, 
which increase their volume and potentiate a multitude of different mechanical 
behaviours, making them an interesting and potentially intelligent (i.e., reactive to 
external stimuli) material to be used as controlled release systems of bioactive 
molecules (Amiriana et al., 2021; Pettinelli et al., 2020).
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Figure 6. Schematic representation of hydrogels nanoparticles (HGs). Purple 
rectangle: crosslinker (hydrophobic interaction, hydrogen bond, electrostatic 
interaction, coordination, host-guest interaction). Blue lines: polymer segments, 
based on Pachioni-Vasconcelos et al. (2015).
Despite their highly hydrophilic nature, HGs allow the incorporation of 
hydrophobic compounds such as CUR, into the gel matrix, encapsulating and 
protecting those until they reach a specific target within the human body (e.g., 
mouth, stomach, liver, prostate, small intestine, and colon). This result in 
increased drugs bioavailability, reduction of side effects, control of kinetic release 
profiles, easy clinical administration, and low costs (Alavi et al., 2018; Feng et al., 
2020). Nowadays, HGs are designed to be oral (most commonly used), 
transdermal, vaginal, and ocular administered. More specifically, HGs when 
injected present a low viscosity liquid and then cross-linked into viscoelastic gels 
through an exposure to different stimuli, specific physiological changes or 
external conditions (e.g., radiation, enzymes, salt, and temperature), while 
protecting cells and bioactives, such as CUR, from the hostile environment due 
to e.g. stomach acidity, enzymes, and immune system activity (Abdel-Wahhab et 
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al., 2019; Cascone and Lamberti, 2020; Pushpalatha et al., 2019; Songkroh et 
al., 2015).
Polysaccharide-based HGs have been intensively studied as site-specific 
delivery agents of CUR because their physicochemical and biological properties 
(e.g., biodegradability, biocompatibility, hydrophilicity, non-toxicity, 
water‐retaining capacity, and mechanical stability) provide unique characteristics 
for medical applications. However, some setbacks were found due to inadequate 
formulations, especially those based on one single biopolymer that often cannot 
show efficient CUR loading and targeted release. For this reason, one or more 
polysaccharides and mechanisms may be used to increase the entrapment 
efficiency and prevent a precocious disintegration, ensuring the release at the 
expected target, i.e., tumour cells (Feng et al., 2020; Liu et al., 2020; Mahmoud 
and Marzok, 2020). Additionally, the polysaccharide HGs’ tuneable structure and 
network morphology offer interesting and adaptable physical properties, such as 
density, refractive index, and rheological properties, when exposed to varying 
environmental conditions (Abaee et al., 2017). On the other hand, mixtures of 
polysaccharide-based structures and proteins have also been widely studied 
(Table 6) to protect and deliver CUR to the final target. Proteins carry a high 
nutritional value, antioxidant capacity, functional properties, amphiphilic nature, 
biocompatibility, biodegradability, low toxicity, and contribute to the chemical and 
photo-stability of CUR (Alavi et al., 2018). 
Colon-targeted HGs as vehicles of drugs such as CUR have emerged due 
to increasing concerns with colon health (Feng et al., 2020). Alavi et al. (2018) 
designed an orally administrated colon-targeted HG delivery system based on 
whey-protein aggregates (WPA)/k-carrageenan (KC) (named as WPA/KC HG) 
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for CUR encapsulation to battle cancer or inflammatory bowel diseases. This 
nanoformulation showed an %EE above 92% and a water holding capacity above 
96%. This work confirmed the importance of adding a polysaccharide to the 
protein-based HG once the physical stability of CUR was highly improved with 
the KC addition. Besides that, WPA/KC HG nanoformulation increased the CUR 
delivery efficiency in the colon, as 87% of the loaded CUR were delivered to the 
colon where colon microorganisms could degrade the complex WPA/KC HG 
network. Additionally, only 3.5% of WPA/KC HG was degraded after the 
gastrointestinal digestion.
Table 6 summarizes the main studies that address the preparation of CUR-
HGs nanoformulations for cancer therapy. The HGs size displayed values of 188 
and 490 nm, with zeta potential values ranging from -34.5 to -5.8 mV, according 
to Table 6. In general, the number of studies with HGs in cancer therapy is still 
low, and therefore, there is an enormous potential to be investigated. In this 
sense, despite the widespread use of HGs as delivery vehicles for bioactive 
compounds, in the particular case of CUR, specifically, there are still many 
possibilities to be explored to improve their performance and specificity. 
Additionally, smart HGs can respond to external stimuli (i.e., light, pH, ultrasound, 
and temperature), allowing in situ gelation, and a more sustained and controlled 
drug release. The studies highlighted by us in Table 6 have shown that these Ns 
release CUR in a controlled and sustained manner, employing 
materials/biomaterials with biodegradable and biocompatible characteristics, 
which is an advantage as a DDS.
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Table 6. Summary of curcumin-loaded hydrogels (HGs) approach for cancer therapy reported in the literature over the past 10 years. 
IC50 corresponds to the half-maximal inhibitory concentration, respectively.
Type of hydrogels systems/Composition Size (nm)
ζ potential 
(mV) IC50 Release results
Cell lines 
evaluated References




Zhou et al. 
(2019)





Chitosan/Chondroitin sulfate conjugated with 




Freitas et al. 
(2020)





Cyclodextrin-based (CB) - - 702.27 mg/mL
The complexes of CUR inclusion resulted in a 
constant release kinetics, independently of the 
drug concentration (~100% after 4 h), 
appropriate for continuous release of 






poly(ethyleneglycol) diacrylate - - -
~6% after 1 day 
55% after 7 days
both without addition of lysozyme
~45% after 1 day
85% after 7 days








lactide) (PCLA-PEG-PCLA) incorporating 
CUR-loaded polyethylene glycol-b-
polylactide (mPEG-PLA)
188.6** -15** 25.5 mg/Kg***
~24.5% for mPEG-PLA after 5 h
66.7% for mPEG-PLA after 240 h 
14.5% for PCLA-PEG-PCLA-mPEG-PLA after 
5 h




Babaei et al. 
(2020)
“-” this parameter was not reported by the authors.
*AgNPs with CUR; **CUR-encapsulated mPEG-PLA nanopolymersomes (Poly-CUR); and ***Suppressed the tumor growth and the tumor volume of mice treated in comparison 
with the original tumor size.
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4.6 Nanocomplexes
In this section, we will consider nanometric structures formed by one type 
of carrier molecule (protein or oligosaccharide), which interacts/aggregates with 
CUR by non-covalent interactions to form a nanoaggregate (or nanocomplexe), 
as depicted in Figure 7. In this sense, the most relevant nanocomplexes that 
enhance CUR solubility involves the use of cyclodextrins (CD). CDs are cyclic 
glucose polymers consisting of six (α-), seven (β-) or eight (γ-) units linked by α-
(1,4) glycosidic bonds, which have an inner cavity that can bind hydrophobic 
molecules, forming stable hydrophilic complexes that enhances CUR water 
solubility (Table 7) and dissolution kinetics (Rocks et al., 2012; Ntoutoume et al., 
2016). Noteworthy, CUR studies focus on solubility and inclusion characterization 
and rarely on measuring the diameter size. However, this measure is essential to 
characterize the aggregation state since particle size depends on concentration 
of CD, complexed drugs, and formulation excipients. In addition, particle size can 
change internalization pathways and targeting, again highlighting the need for 
better characterization of these complexes concerning their size profile (Zaman 
et al., 2017).
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Figure 7. Schematic representation of polymeric β‐cyclodextrin/curcumin 
(PCD/CUR) self‐assembly through the inclusion complexation mechanism 
formation, based on Yallapu et al. (2010).
Table 7. Curcumin solubility in different cyclodextrins (CD).
CD type Solubility (mM) Reference
β-CD ~0.05 (20 mM CD)
γ-CD ~0.15 (20 mM CD)
Hydroxypropyl-β-CD ~0.32 (20 mM CD)
Methyl-β-CD ~0.51 (20 mM CD)
Yadav et al. (2009)*
β-CD 1.12 (60 mM CD) Mangolim et al. (2014)**
Hydroxypropyl-γ-CD 1.98 (57 mM CD)
Hydroxypropyl-β-CD 0.27 (70 mM CD)
Singh et al. (2010)***
*Solubility in aqueous solution. Values obtained from the phase solubility diagram of curcumin–CD 
complexes. **Solubility in aqueous solution. ***Solubility in phosphate buffer (0.1 M, ionic strength 0.3) pH 6.0.
CUR-β-CD complexes (%DL of 15%) were shown to increase molecule 
solubility and antitumor activity against lung tumor provoked by H22 cells in mice. 
The enhancement elucidated in vitro (A549 cells) was related to improved cellular 
uptake and modified-release kinetics (Zhang et al., 2016). Polymeric β-CD were 
also complexed with CUR and formed NSs of 250 nm in higher CUR 
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concentrations, with a %DL of 23% (i.e., 223.2 µg of CUR per mg of CD). It 
reached an 80-fold enhanced solubility and an improved in vitro stability at 
physiological pH conditions: after 72 h immersed in PBS buffer, almost 100% of 
free CUR precipitated, whereas only 11% of the complexed CUR precipitated. As 
for monomeric β-CDs, the polymeric complex showed higher antitumor and 
cytotoxic activity than free CUR in prostate cancer cells. The IC50 values for 
prostate cancer cell lines C4-2, DU145, and PC3 were 19.6, 19.25, and 19.4×10-6 
M for free CUR and 12.5, 15.9, and 16.1×10-6 M for CUR complexed with β-CD, 
respectively (Yallapu et al., 2010). 
CUR-Hydroxypropyl-β-CD (HP-β-CD) complexes showed an even higher 
solubility (202-fold) and a modified dissolution profile of 50% release in 6 h, with 
100% of CUR dissolved in 12 h. In addition, complexation increased the biological 
effects, demonstrated by greater antiangiogenic effects than free CUR in chick 
chorioallantoic membrane model and by the decrease in the disease’ extent and 
severity in a rat colitis model (histopathological outcomes) (Yadav et al., 2009).
Rocks et al. (2012) treated implanted tumors in mice with CUR-
hydroxypropyl-γ-cyclodextrin (CUR-HP-γ-CD)-gemcitabine complexes, as the 
treatment inhibited lung tumor growth. The association of CUR-HP-γ-CD and 
gemcitabine presented a 2-fold reduction of cell proliferation in mice lung tumors 
compared to the vehicle or non-soluble CUR treatments. However, there was no 
report of physicochemical characteristics of the formulation.
Concerning other nanoaggregates, the stability and aqueous solubility of 
CUR was significantly improved in the presence of proteins, which are folded in 
nanostructured particles, as result this molecule is encapsulated. Some of these 
proteins are not yet widely employed in cancer therapy, however, some of them 
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have been used to increase CUR solubility and stability. In particular, CUR 
formulations with pea and zein proteins have been studied, showing increased 
solubility, photo and thermal stability. The results generated have been 
interesting and have shown great potential for their use in the near future. Thus, 
for the interested reader, we would like to recommend some articles on the topic: 
Guo et al. (2021); Liu et al. (2018); Rafiee et al. (2018); Vijaian et al. (2021); Wang 
et al. (2019).
Moreover, as in most CDs studies, protein-CUR complexes generally lack 
physicochemical measurements such as size, particle charge, or drug release 
kinetics. For instance, CUR-casein complexes do not present these 
physicochemical indications. However, the work showed that complexation 
increased the half-life of CUR in Tris-HCl buffer (pH 7.2) approximately 39-fold 
(i.e., from 8.8 min to 340 min), and degradation rates decreased from 90% after 
30 min to 55% after 6 h of incubation (Sneharani et al., 2009). CUR combined 
with BSA was also protected from degradation, showing only 24% degradation 
after 1,000 min in sodium phosphate buffer (pH 7.0), whereas free CUR 
decomposes by 53% (Yang et al., 2013).
Chen et al. (2014) encapsulated CUR in the inner cavity of recombinant 
human H-chain ferritin presented the smallest size of measured CUR-protein 
complexes (12 nm), but low %EE (14.7%), and %DL of 1.07%. These 
nanoparticles increase CUR water solubility about 492-fold and improved its 
photo-stability: 69% of free CUR degraded after 50 min when exposed to an 
incandescent lamp, whereas only 11% of complexed CUR was degraded.
Protein complexes may perform better with surfactants like dextran, which 
diminish undesired aggregation. Yi et al. (2016) studied the effect of CUR coating 
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with α-lactalbumin or α-lactalbumin-dextran complex on its stability. The protein 
coating formed a nanocomplex of 63.5 nm (PDI of 0.108, ζ potential of -13.9 mV, 
and %EE of 97.5%), while CUR coated with α-lactalbumin and dextran showed a 
size of 68.1 nm (PDI of 0.161, ζ potential of -10.5 mV, and %EE of 98.8%). CUR 
coated with α-lactalbumin-dextran presented no changes in the mean particle 
diameters upon heating for 30 min (70, 80, and 90ºC) or when submitted to pH 
variations, performing better than the pure protein coating. However, both 
nanocomplexes exhibit less degradation in water dispersion after 4 h storage: 
91.7% of CUR remained in α-lactalbumin complex, and 92.1% in α-lactalbumin-
dextran conjugates, while only 24.8% was left when free CUR was used. 
A study of CUR bonded in another globulin (β) presented the formation of 
bigger nanoparticles (142 nm) but also high %EE (>96%). CUR stability in 50 mM 
Tris-HCl buffer (pH 7.0) was increased by 6.7 times when in its complex form, 
and its water solubility was enhanced by ~20,800 times (Sneharani et al., 2010). 
Another high encapsulation formulation was CUR-soy protein complex (%EE of 
96.8 to 99.1%, with %DL of 1.743 to 1.784 μg/mg of soy protein). The dried 
nanocomplex prepared with a protein concentration of 1.0% (w/v), improved the 
CUR water solubility about 1600-fold. The complex size was about 90 nm, and 
the ζ potential was between -10.95 and -13.20 mV.
Despite a few studies to date applied to cancer therapy, these results 
based on CUR in nanocomplexes may present promising DDS platforms for 
treatment of tumor cells. This approach is expected to be of wide applicability to 
this important class of Ns where CUR solubility is enhanced by CD and other 
excipients as well as to allow using a low-dose bioavailable CUR that is preferable 
to reduce potential side effects.
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5. Final considerations
CUR has several interesting properties for medical applications, including 
antimicrobial, antioxidant, anti-inflammatory, and excellent antitumoral activity. 
However, it presents several drawbacks (e.g., low solubility in water and 
instability), which challenge the creation of stable formulations for commercial 
medical products.
In the last 10 years, several research groups around the world have been 
proposing different nanocarriers to encapsulate CUR to improve its efficacy as a 
therapeutic agent against cancer. As shown in this review, CUR 
nanoformulations demonstrated superior therapeutic effects against cancer 
compared to the drug's free form. CUR interferes with the proliferation and 
survival of tumor cells, both directly and indirectly, due to its capacity to interact 
with various targets such as growth factors, DNA, RNA, transcription factors, and 
diverse biomolecules involved in cell signal transduction pathways.
As detailed previously, CUR has been encapsulated in micelles and 
liposomes for antitumoral use because of their interesting features such as high 
loading capacity, good stability, easy preparation, and low PDI values. These Ns 
types will probably persist in the future, mainly with responsive approaches to 
external stimuli (e.g., pH, temperature, etc.). However, novel nanosystems can 
be designed and demonstrate better responses in cancer therapy. In this sense, 
we pointed out potential nanocarriers of different compositions with or without 
target ligands developed for the encapsulation and release of CUR, such as: 
epidermal growth factor (EGF)-conjugated chitosan NSs, mesoporous silica 
nanocarrier composed by chitosan, folate conjugated poly-D,L-lactic-co-glycolic 
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acid (PLGA) NSs, Gemini surfactants micelles, dendrosomes, nanosuspensions, 
solid lipid nanoparticles, polymeric nanoparticles, phytosomes, cubosomes, and 
inorganic nanoparticles. Besides the inherent advantages of Ns for 
encapsulation, some works mentioned in this review show that it is feasible to 
design them to deliver CUR to target sites through pH-responsive, thermo-
responsive, and other methods, improving the delivery and, consequently, and 
diminishing side effects, illustrating how CUR nanoformulation can become more 
attractive in the future for antitumoral treatments.
Another important consideration is that in classical chemotherapy 
treatments, the combination of drugs with synergic effects is widely used, aiming 
at greater cellular death. Hence, CUR nanoformulations in cancer therapy were 
combined with other antineoplastic drugs, like doxorubicin, docetaxel, and 
paclitaxel. As highlighted before, this combination of antineoplastic drugs and 
CUR can improve antitumor effects and reduce dose-limiting toxicity. Additionally, 
combinations can overcome drug resistance that is common in classical 
chemotherapy. Thus, we also believe that the combination with other drugs will 
continue to be a strong trend for CUR nanoformulations.
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